Inventor · disambiguated record
Marc Martinell Pedemonte
Also filed as: MARTINELL PEDEMONTE MARC
17 granted patents·13 pending applications·102 citations·filing 2008–2024
93Inventor score
Files withMINORYX THERAPEUTICS S L12ORYZON GENOMICS SA12FYFE MATTHEW COLIN THOR2MAES TAMARA2AYMAMI BOFARULL JUAN1
Top patents by PatentIndex Score
30 records- 0189US9782395B22,4-thiazolidinedione derivatives in the treatment of central nervous system disordersMINORYX THERAPEUTICS S L·Filed 2016·Granted Oct 10, 2017·13 cites·22 claims
- 0289US9670136B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2016·Granted Jun 6, 2017·8 cites·26 claims
- 0389US9181198B2Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical useORTEGA MUÑOZ ALBERTO·Filed 2011·Granted Nov 10, 2015·17 cites·63 claims
- 0489US9006449B2Cyclopropylamine derivatives useful as LSD1 inhibitorsFYFE MATTHEW COLIN THOR·Filed 2011·Granted Apr 14, 2015·19 cites·26 claims
- 0587US9708309B2Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical useORYZON GENOMICS SA·Filed 2015·Granted Jul 18, 2017·7 cites·12 claims
- 0686US9676701B2Cyclopropylamine derivatives useful as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2015·Granted Jun 13, 2017·7 cites·20 claims
- 0786US9487512B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2012·Granted Nov 8, 2016·8 cites·60 claims
- 0886US9469597B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2012·Granted Oct 18, 2016·8 cites·14 claims
- 0984US9944601B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2016·Granted Apr 17, 2018·4 cites·19 claims
- 1078US9908859B2Lysine demethylase inhibitors for myeloproliferative disordersORYZON GENOMICS SA·Filed 2014·Granted Mar 6, 2018·6 cites·16 claims
- 1177US10179126B22,4-thiazolidinedione derivatives in the treatment of central nervous system disordersMINORYX THERAPEUTICS S L·Filed 2017·Granted Jan 15, 2019·2 cites·26 claims
- 1276US10329256B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2018·Granted Jun 25, 2019·1 cites·19 claims
- 1375US10214477B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2017·Granted Feb 26, 2019·1 cites·8 claims
- 1474US10233178B2Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical useORYZON GENOMICS SA·Filed 2017·Granted Mar 19, 2019·1 cites·5 claims
- 1569US2025064791A15-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseasesMINORYX THERAPEUTICS S L·Filed 2024·Application pending·0 cites
- 1668US2024091210A1Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its saltsMINORYX THERAPEUTICS S L·Filed 2023·Application pending·0 cites
- 1755US11938122B25-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver diseaseMINORYX THERAPEUTICS S L·Filed 2017·Granted Mar 26, 2024·0 cites·13 claims
- 1854US2014163041A1Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disordersFYFE MATTHEW COLIN THOR·Filed 2012·Application pending·0 cites
- 1953US2011105544A1Carboxylic derivatives for use in the treatment of cancerAYMAMI BOFARULL JUAN·Filed 2008·Application pending·0 cites
- 2053US2019255032A12,4-Thiazolidinedione Derivatives in the Treatment of Central Nervous System DisordersMINORYX THERAPEUTICS S L·Filed 2018·Application pending·0 cites
- 2153US2017209432A1Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disordersORYZON GENOMICS SA·Filed 2016·Application pending·0 cites
- 2252US11957670B25-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseasesMINORYX THERAPEUTICS S L·Filed 2019·Granted Apr 16, 2024·0 cites·18 claims
- 2350US2021228558A1Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its saltsMINORYX THERAPEUTICS S L·Filed 2019·Application pending·0 cites
- 2448US2021308113A1Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dioneMINORYX THERAPEUTICS S L·Filed 2019·Application pending·0 cites
- 2548US2023172921A1Leriglitazone for treating lung inflammation and interstitial lung diseaseMINORYX THERAPEUTICS S L·Filed 2021·Application pending·0 cites
- 2645US2014296255A1Lysine demethylase inhibitors for thrombosis and cardiovascular diseasesMAES TAMARA·Filed 2012·Application pending·0 cites
- 2745US2014329833A1Lysine demethylase inhibitors for inflammatory diseases or conditionsMAES TAMARA·Filed 2012·Application pending·0 cites
- 2841US2016000768A1Cyclopropylamine inhibitors of oxidasesORYZON GENOMICS SA·Filed 2015·Application pending·0 cites
- 2938US2016168132A1Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereofMINORYX THERAPEUTICS S L·Filed 2014·Application pending·0 cites
- 3036US11440898B2Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidaseMINORYX THERAPEUTICS S L·Filed 2017·Granted Sep 13, 2022·0 cites·23 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →